CA3233866A1 - Treatment of kidney disease - Google Patents

Treatment of kidney disease Download PDF

Info

Publication number
CA3233866A1
CA3233866A1 CA3233866A CA3233866A CA3233866A1 CA 3233866 A1 CA3233866 A1 CA 3233866A1 CA 3233866 A CA3233866 A CA 3233866A CA 3233866 A CA3233866 A CA 3233866A CA 3233866 A1 CA3233866 A1 CA 3233866A1
Authority
CA
Canada
Prior art keywords
patient
egfr
approximately
kidney
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233866A
Other languages
English (en)
French (fr)
Inventor
Timothy A. Bertram
Deepak Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3233866A1 publication Critical patent/CA3233866A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0684Cells of the urinary tract or kidneys
    • C12N5/0686Kidney cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
CA3233866A 2021-10-14 2022-10-14 Treatment of kidney disease Pending CA3233866A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163255885P 2021-10-14 2021-10-14
US63/255,885 2021-10-14
US202263307801P 2022-02-08 2022-02-08
US63/307,801 2022-02-08
US202263321204P 2022-03-18 2022-03-18
US63/321,204 2022-03-18
PCT/US2022/078153 WO2023064925A1 (en) 2021-10-14 2022-10-14 Treatment of kidney disease

Publications (1)

Publication Number Publication Date
CA3233866A1 true CA3233866A1 (en) 2023-04-20

Family

ID=85988933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233866A Pending CA3233866A1 (en) 2021-10-14 2022-10-14 Treatment of kidney disease

Country Status (8)

Country Link
US (1) US20250009803A1 (https=)
EP (1) EP4415729A4 (https=)
JP (1) JP2024536479A (https=)
KR (1) KR20240110801A (https=)
AU (1) AU2022362077A1 (https=)
CA (1) CA3233866A1 (https=)
MX (1) MX2024004355A (https=)
WO (1) WO2023064925A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106530A1 (en) * 2023-11-13 2025-05-22 Butler Emily Characteristics of enriched heterogeneous renal cell populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020266168A1 (en) * 2019-05-02 2021-12-02 ProKidney IPCo, LLC Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies

Also Published As

Publication number Publication date
WO2023064925A1 (en) 2023-04-20
US20250009803A1 (en) 2025-01-09
JP2024536479A (ja) 2024-10-04
KR20240110801A (ko) 2024-07-16
EP4415729A4 (en) 2025-08-27
WO2023064925A8 (en) 2024-04-11
AU2022362077A1 (en) 2024-05-02
EP4415729A1 (en) 2024-08-21
MX2024004355A (es) 2024-06-21

Similar Documents

Publication Publication Date Title
Skyler et al. Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study
Ulus et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART Trial)
Crisostomo et al. Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells
US20140335058A1 (en) Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
EP4181935A1 (en) Methods and compositions for treating lung conditions
US20250288616A1 (en) Bioactive renal cells for the treatment of chronic kidney disease
Khalili et al. Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period
US20100111908A1 (en) Induction of Renal Cells for Treatment of Kidney Disease
US20250009803A1 (en) Treatment of kidney disease
US20070172447A1 (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
Stavas et al. Renal autologous cell therapy to stabilize function in diabetes-related chronic kidney disease: corroboration of mechanistic action with cell marker analysis
Scott-Emuakpor et al. Role of oral retinoids in treatment of acne vulgaris with a bioinformatics-based perspective of personalized medicine
CN118354777A (zh) 肾脏疾病的治疗
HK40113884A (zh) 肾脏疾病的治疗
Schmid et al. New strategies for managing anemia of chronic kidney disease
MARYNIAK et al. RECURRENCE OF DIABETIC NODULAR: GLOMERULOSCLEROSIS IN A RENAL TRANSPLANT
KR20240034745A (ko) 동물의 골관절염 치료용 중간엽 줄기세포
US20240299328A1 (en) Compositions comprising 15-hepe and methods of treating and/or preventing hematologic disorders and related diseases
DiCarlo et al. Acute kidney injury in pediatric stem cell transplant recipients
CN114350607B (zh) 骨髓来源的成熟b细胞及其在制备治疗心肌梗死的药物中的应用
TWI780431B (zh) 新穎性醫藥組合物及其於修復肝臟損傷、治療肝臟損傷相關疾病與提升肝臟功能之用途
Gariani et al. Impact of Islet Transplantation on Type 1 Diabetes-Related Complication: A Systematic Review
RU2833560C1 (ru) Композиции, содержащие 15-hepe, для лечения или профилактики гематологических нарушений и/или связанных заболеваний
Raafat et al. SGLT2 Inhibitors and Myocardial Infarction in Diabetes: Current Insights into Cardioprotective Mechanisms
US20230094263A1 (en) Methods For Treating Coronavirus Disease

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240904

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010